Electromedical
Technologies Introduces the WellnessPro Infinity™
Development
of Revolutionary Next-Gen Electrotherapy Device Fully
Complete
Company
expects to start filling orders in Q1 2023
SCOTTSDALE, AZ -- October
31, 2022 -- InvestorsHub NewsWire -- Electromedical Technologies,
Inc. (OTCQB:
EMED)
("Electromedical" or the "Company"), a pioneer in the development
and production of bioelectronic devices designed to relieve
chronic, intractable, and acute pain through frequency and
electro-modulation, is very excited to introduce its new
next-generation flagship device, the WellnessPro
Infinity™.
See the WellnessPro
Infinity™ https://electromedtech.com/wp-infinity/
"The WellnessPro Infinity™
will set an entirely new standard in the Bioelectronics
marketplace" remarked Electromedical Founder and CEO,
Matthew Wolfson. "There's nothing like it on the market in terms of
capability, flexibility, ease of use, and doctor-patient interface.
And most important of all - Patient results. "
The NEW WellnessPro
Infinity™ device features:
-
One
compact device that encompasses ALL electrotherapy
modalities.
-
Can
produce any frequency, any wave form (typical or atypical), any
level of modulation
-
Designed to
support: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD
Laser, POD Synchronization, IDNA™,
Deep
Pluse™, Cloud access and much more.
-
Unprecedented
accuracy.
-
Easiest
to use electrotherapy device on the market.
-
New
Doctor-Patient Portal for updates and personalized
treatments.
Wolfson added, " I want to
thank our shareholders for the continued support, everyone at EMED
and especially our incredible engineering team in Europe, for the
hard work, innovation and long hours our team put in, to create a
device we believe will help millions of people live happier
healthier Pain Free lives and help battle the Opioid
epidemic. Now that we have completed development
of our NEW flagship model by October as planned, the next step is
electrical laboratory safety testing. After that, it will be
production ready. Once production is underway, we will begin taking
pre orders. Our goal is to start shipping units next quarter. POD
development is going as planned and we look forward to sharing
progress in our upcoming press releases soon. Our goal is to go to
market with the WellnessPro Infinity™ first, then shortly after
releasing the POD upon FDA 510k clearance."
About
Electromedical Technologies
Headquartered in Scottsdale,
Arizona, Electromedical Technologies, Inc. is a commercial stage,
FDA cleared, bioelectronic medical device manufacturing company
initially focused on the treatment of various chronic, acute,
intractable, and post-operative pain conditions. Through University
collaboration agreements, the Company is working to develop a
comprehensive research program in defining the effects of
electro-modulation on the human body. By studying the impacts of
electrical fields in cell signaling and effects on virus assembly
and immune responses, the Company's goal is to reduce pain and
improve overall human wellbeing. The Company's current FDA cleared
product indications are for chronic acute post traumatic and
post-operative, intractable pain relief.
For more information, please
visit
www.electromedtech.com.
Note: Nonhuman preliminary
studies that we are planning to start in the near future and their
applications are not related to our current product in any way and
are currently not cleared in the US.
Safe
Harbor Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
or guarantee that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous factors and uncertainties,
including but not limited to: adverse economic conditions,
competition, adverse federal, state and local government
regulation, international governmental regulation, inadequate
capital, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and
other specific risks. To the extent that statements in this press
release are not strictly historical, including statements as to
revenue projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
events conditioned on stockholder or other approval, or otherwise
as to future events, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made.
Corporate
Contact:
Electromedical Technologies,
Inc.
Tel:
1.888.880.7888
Email:
ir@electromedtech.com
https://electromedtech.com